Study Summaries

GOG 240: Bevacizumab in Advanced Cervical Cancer

The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer improved median overall survival by 3.7 months and was associated with higher response rates.

Tata Memorial Hospital Trial: Neoadjuvant Chemo + Surgery vs. ChemoRT

Cisplatin-based concomitant chemoradiation resulted in superior DFS compared to neoadjuvant chemotherapy followed by radical surgery in patients with locally advanced cervical cancer.

UTERUS-11: Surgical versus clinical staging before primary chemoradiation

GROINS V II: Radiotherapy Versus Inguinofemoral Lymphadenectomy

Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, showing minimal morbidity. However, for patients with SN macrometastasis, radiotherapy alone resulted in more isolated groin recurrences compared to IFL.

GOG 92: Sedlis Criteria Study

Adjuvant pelvic radiotherapy significantly reduces the risk of cancer recurrence in women with Stage IB cervical cancer who have undergone radical hysterectomy and pelvic lymphadenectomy and possess specific high-risk factors. The treatment is associated with higher but acceptable morbidity.

SIENDO Trial: Selinexor in TP53wt Advanced or Recurrent Endometrial Cancer

Landoni Trial: Radical Surgery versus Radiotherapy for Stage Ib-IIa Cervical Cancer

There is no clear treatment of choice for early-stage cervical carcinoma in terms of overall or disease-free survival. Treatment should be tailored to individual patient factors such as menopausal status, age, medical conditions, histological type, and cervical diameter to achieve the best outcomes

CONCERV Trial

Conservative surgery is feasible for select patients with early-stage, low-risk cervical cancer